Summary of Purchase Price Acquisition (Details) - USD ($) |
3 Months Ended | |||||
|---|---|---|---|---|---|---|
Jul. 28, 2026 |
Sep. 30, 2026 |
|||||
| Asset Acquisition [Line Items] | ||||||
| Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition | ||||||
| Common Stock [Member] | ||||||
| Asset Acquisition [Line Items] | ||||||
| Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition | ||||||
| Vidya Therapeutics, Inc. [Member] | ||||||
| Asset Acquisition [Line Items] | ||||||
| Total consideration | [1] | $ 175,000,000 | ||||
| Cash acquired | (102,000) | |||||
| Business Combination, Recognized Liability Assumed, Liability | 467,000 | |||||
| Net liabilities and IPR&D acquired | 175,365,000 | |||||
| Vidya Therapeutics, Inc. [Member] | Common Stock [Member] | ||||||
| Asset Acquisition [Line Items] | ||||||
| Fair value of the options to purchase Vidya common stock we assumed | $ 1,280 | |||||
| Series A Preferred Stock [Member] | ||||||
| Asset Acquisition [Line Items] | ||||||
| Multiplied by the fair value per share of our Series A Preferred Stock | [2] | $ 1.22119 | ||||
| Series A Preferred Stock [Member] | Vidya Therapeutics, Inc. [Member] | ||||||
| Asset Acquisition [Line Items] | ||||||
| Number of shares of Series A Preferred Stock issued to the Vidya shareholders and option holders, as converted | 142,254,972 | |||||
| Fair value of Series A Preferred Stock issued to effect the Vidya Acquisition | $ 173,720 | |||||
| Total consideration | $ 175,000,000 | |||||
| ||||||